Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer (Q90300758)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

title

Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

1 reference

William J Kelly

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Neil J Shah

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

Deepa S Subramaniam

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

publication date

3 July 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

published in

Frontiers in Oncology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

page(s)

208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution 4.0 International

12 April 2020

start time

3 July 2018

1 reference

April 2022 Public Data File from Crossref

copyrighted

0 references

cites work

Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).

1 reference

12 December 2020

Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).

1 reference

12 December 2020

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

1 reference

12 December 2020

Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial

1 reference

12 December 2020

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

1 reference

12 December 2020

Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer

1 reference

12 December 2020

Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases

1 reference

12 December 2020

Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity

1 reference

12 December 2020

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

1 reference

12 December 2020

Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

1 reference

12 December 2020

Erlotinib in previously treated non-small-cell lung cancer

1 reference

12 December 2020

Frequent EGFR mutations in brain metastases of lung adenocarcinoma

1 reference

12 December 2020

Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib

1 reference

12 December 2020

Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain

1 reference

12 December 2020

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

1 reference

12 December 2020

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

1 reference

12 December 2020

Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer

1 reference

12 December 2020

Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population

1 reference

12 December 2020

Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis

1 reference

12 December 2020

Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer.

1 reference

12 December 2020

HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors

1 reference

12 December 2020

Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib

1 reference

12 December 2020

High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer

1 reference

12 December 2020

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation.

1 reference

12 December 2020

Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

1 reference

12 December 2020

BIBW 2992 in non-small cell lung cancer

1 reference

12 December 2020

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

1 reference

12 December 2020

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

1 reference

12 December 2020

"Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer.

1 reference

12 December 2020

Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features

1 reference

12 December 2020

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation

1 reference

12 December 2020

Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer

1 reference

12 December 2020

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

1 reference

12 December 2020

EGFR mutation status in brain metastases of non-small cell lung carcinoma.

1 reference

12 December 2020

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers

1 reference

12 December 2020

Bevacizumab and central nervous system (CNS) hemorrhage

1 reference

12 December 2020

Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer

1 reference

12 December 2020

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

1 reference

12 December 2020

Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis

1 reference

12 December 2020

Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma

1 reference

12 December 2020

Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors

1 reference

12 December 2020

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

1 reference

12 December 2020

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

1 reference

12 December 2020

The concentration of erlotinib in the cerebrospinal fluid of patients with brain metastasis from non-small-cell lung cancer

1 reference

12 December 2020

Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma

1 reference

12 December 2020

Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.

1 reference

12 December 2020

Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer

1 reference

12 December 2020

Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated non-small-cell lung cancer patients with brain metastases or leptomeningeal disease

1 reference

12 December 2020

Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.

1 reference

12 December 2020

Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial

1 reference

12 December 2020

EGFR tyrosine kinase inhibitors versus cranial radiation therapy for EGFR mutant non-small cell lung cancer with brain metastases: a systematic review and meta-analysis

1 reference

12 December 2020

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

1 reference

12 December 2020

Rociletinib in EGFR-mutated non-small-cell lung cancer

1 reference

12 December 2020

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

1 reference

12 December 2020

Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?

1 reference

12 December 2020

Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium

1 reference

12 December 2020

Five-Year Survival in EGFR-Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs

1 reference

12 December 2020

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

1 reference

12 December 2020

Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis

1 reference

12 December 2020

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

1 reference

12 December 2020

Impact of whole brain radiation therapy on CSF penetration ability of Icotinib in EGFR-mutated non-small cell lung cancer patients with brain metastases: Results of phase I dose-escalation study

1 reference

12 December 2020

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial

1 reference

12 December 2020

Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity

1 reference

12 December 2020

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

1 reference

12 December 2020

The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

1 reference

12 December 2020

Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis

1 reference

12 December 2020

Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis.

1 reference

12 December 2020

AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases

1 reference

12 December 2020

Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

1 reference

12 December 2020

Phase 1 study of twice weekly pulse dose and daily low-dose erlotinib as initial treatment for patients with EGFR-mutant lung cancers

1 reference

12 December 2020

Management of Brain Metastases in Tyrosine Kinase Inhibitor-Naïve Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

1 reference

12 December 2020

A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer

1 reference

12 December 2020

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

1 reference

12 December 2020

Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial

1 reference

12 December 2020

Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer

1 reference

12 December 2020

Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment

1 reference

12 December 2020

High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases

1 reference

12 December 2020

Strategies targeting angiogenesis in advanced non-small cell lung cancer

1 reference

12 December 2020

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis.

1 reference

12 December 2020

The molecular mechanisms of chemoresistance in cancers

1 reference

12 December 2020

Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients

1 reference

12 December 2020

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

1 reference

12 December 2020

Identifiers

DOI

10.3389/FONC.2018.00208

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json

12 April 2020

PubMed publication ID

30018881

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30018881%20AND%20SRC:MED&resulttype=core&format=json